Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States

References

• NIH National Cancer Institute. SEER Cancer Statistics Factsheets: lung and bronchus cancer. http://seer.cancer.gov/statfacts/html/lungb.html. Accessed July 13, 2016
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al, Surveillance, Epidemiology, and End Results (SEER) Program. SEER Cancer Statistics Review, 1975-2012 (updated August 20, 2015). National Cancer Institute, Bethesda, MD, based on November 2014 SEER data submission, posted to the SEER web site, April 2015. Available at: http://seer.cancer.gov/csr/1975_2012/. Accessed July 13, 2016
   Google Scholar
• Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005;23:3270-8
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN guidelines: non-small cell lung cancer version 4.2016. US, 2016. Available at: http://www.jnccn.org/content/suppl/2016/03/08/14.3.255.DC1/255.pdf. Accessd July 13, 2016
   Google Scholar
• McKay C, Burke T, Cao X, et al. Treatment patterns for advanced non-small-cell lung cancer after platinum-containing therapy in U.S. Community Oncology Clinical Practice. Clin Lung Cancer Forthcoming 2016
   Google Scholar
• Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009;14:253-63
   PubMed Web of Science ®Google Scholar
• Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-28
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE 010): a randomised controlled trial. Lancet 2016; 3871540-50
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). NICE guide to methods of technology appraisal, UK, 2013. Available at http://www.nice.org.uk/article/pmg9/chapter/foreword. Accessed July 13, 2016
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of healthtechnologies: Canada, 3rd edn. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006
   Google Scholar
• Hui R, Gandhi L, Carcereny Costa E, et al. [Abstract] Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro). J Clin Oncol 2016;34(Suppl):abstr 9026
   Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient-level data. Sheffield: Report by the Decision Support Unit, 2011. http://docplayer.net/11340696-Nice-dsu-technical-support-document-14-survival-analysis-for-economic-evaluations-alongside-clinical-trials-extrapolation-with-patient-level-data.html. Accessed July 13, 2016
   Google Scholar
• National Institute for Health and Care Excellence. Single Technology Appraisal: evidence review group report. Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer. NICE, UK, 2014. Available at: https://www.nice.org.uk/guidance/indevelopment/gid-tag449. Accessed July 13, 2016
   Google Scholar
• National Institute for Health and Care Excellence. NICE Single Technology Appraisal. Nivolumab for previously treated locally advanced or metastatic squamous non-small-cell lung cancer. NICE, UK, 2015. https://www.nice.org.uk/guidance/indevelopment/gid-tag506/documents. Accessed July 13, 2016
   Google Scholar
• NIH National Cancer Institute. SEER Data, 1973-2013, US, 2015. http://seer.cancer.gov/data/. Accessed July 13, 2016
   Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84.
   PubMed Web of Science ®Google Scholar
• Hatswell AJ, Pennington B, Pericleous L, et al. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes 2014;12:140
   PubMed Web of Science ®Google Scholar
• Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005;43:203-20
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. MedCare 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Euro J Health Econ 2003;4:222-31
   PubMedGoogle Scholar
• Bureau of Labor Statistics. Consumer Price Index, US, 2016. Available at http://www.bls.gov/cpi/. Accessed July 13, 2016
   Google Scholar
• Flatiron database. Flatiron Health, US, 2015. http://www.flatiron.com/life-sciences. Accessed May 12, 2015
   Google Scholar
• Centers for Medicare & Medicaid Services, (CMS), US, FY2016.. https://www.cms.gov/apps/ama/license.asp?file/Medicare/Medicare-Fee-for-Service-Part-BDrugs/McrPartBDrugAvgSalesPrice/downloads/2016-July-ASPPricing-File.zip. Accessed July 13, 2016
   Google Scholar
• Ramsey S, Henk HJ, Smith GL, et al. First-, second-and third-line lung cancer treatment patterns and associated costs in a US healthcare claims database. Lung Cancer Manage 2015;4:131-43
   Web of Science ®Google Scholar
• AnalySource. Suite of drug pricing services, US, 2016. http://www.Analysource.com. Accessed July 13, 2016
   Google Scholar
• Chastek B, Harley C, Kallich J, et al. health care costs for patients with cancer at the end of life. J Oncol Pract 2012;8:75s-80s
   PubMedGoogle Scholar
• Kim SH, Jo MW, Kim HJ, et al. Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes 2012;10:151
   PubMed Web of Science ®Google Scholar
• Braithwaite RS, Meltzer DO, King JT, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 2000;9:235–51
   Google Scholar
• KNOEMA. IMF World Economic Outlook (WEO), US, 2016. https://knoema.com/pjeqzh/gdp-per-capita-by-country-1980-2014. Accessed July 13, 2016.
   Google Scholar
• Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - The curious resilience of the $50,000-per-QALY threshold. New Engl J Med 2014;371:796-7
   PubMed Web of Science ®Google Scholar
• Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modelling approaches to estimate and extrapolate survival outcomes. J Med Econ 2016;19:630-44
   PubMed Web of Science ®Google Scholar